Kannalife, Inc. (KLFE)
Stock Price:
$0.473 USD
-0.027 (-5.31%)
Updated Oct 19, 2020 3:42 PM EDT - Market closed
Key Info
| Market Cap |
35.12M |
| Revenue (ttm) |
23,968 |
| Net Income (ttm) |
-4.18M |
| Shares Out |
74.25M |
| EPS (ttm) |
-0.06 |
| PE Ratio |
n/a |
| Forward PE |
n/a |
| Dividend |
n/a |
| Dividend Yield |
n/a |
Stock Quote
| Trading Day |
Oct 19, 2020 |
| Last Price |
$0.473 |
| Previous Close |
$0.500 |
| Change ($) |
-0.027 |
| Change (%) |
-5.31% |
| Day's Open |
0.500 |
| Day's Range |
0.450 - 0.500 |
| Day's Volume |
48,346 |
| 52-Week Range |
0.37 - 5 |
More Stats
| Market Cap |
35.12M |
| Enterprise Value |
n/a |
| Earnings Date (est) |
n/a |
| Ex-Dividend Date |
n/a |
| Shares Outstanding |
74.25M |
| Float |
15.52M |
| EPS (basic) |
n/a |
| EPS (diluted) |
-0.06 |
| FCF / Share |
n/a |
| Dividend |
n/a |
| Dividend Yield |
n/a |
| Earnings Yield |
n/a |
| FCF Yield |
n/a |
| Payout Ratio |
n/a |
| Shares Short |
n/a |
| Short Ratio |
n/a |
| Short % of Float |
n/a |
| Beta |
2.53 |
| PE Ratio |
n/a |
| Forward PE |
n/a |
| P/FCF Ratio |
n/a |
| PS Ratio |
1,465.30 |
| PB Ratio |
n/a |
| Revenue |
23,968 |
| Operating Income |
n/a |
| Net Income |
-4.18M |
| Free Cash Flow |
n/a |
| Net Cash |
n/a |
| Net Cash / Share |
n/a |
| Gross Margin |
-1,413.03% |
| Operating Margin |
n/a |
| Profit Margin |
n/a |
| FCF Margin |
n/a |
| ROA |
-234.16% |
| ROE |
-504.63% |
| ROIC |
n/a |
Stats based on trailing-twelve-month (ttm) numbers.
Analyst Summary
Analyst Ratings (0)
| Buy |
0 |
| Overweight |
0 |
| Hold |
0 |
| Underweight |
0 |
| Sell |
0 |
*No analysts have provided price targets for this stock.
Financial Overview
No financial data available for this stock yet.
Company Details
| Full Name |
Kannalife, Inc. |
| Country |
United States |
| Employees |
5 |
| CEO |
Dean Petkanas |
Stock Information
| Ticker Symbol |
KLFE |
| Stock Exchange |
US OTC |
| Sector |
Healthcare |
| Industry |
Biotechnology |
| Unique Identifier |
OTCMKTS: KLFE |
Description
Kannalife, a biopharmaceutical company, focuses on the discovery, development, and commercialization of novel therapeutics from its proprietary cannabinoid product platform. It engages in the research and development of chemical entities, such as KLS-13019, as well as its related molecules; and synthetic cannabidiol therapeutics through pre-clinical drug discovery and development processes for use in the disease indications of Overt Hepatic Encephalopathy, Chronic Traumatic Encephalopathy, and Chemotherapy Induced Peripheral Neuropathy. The company was formerly known as TYG Solutions Corp. and changed its name to Kannalife, Inc. in January 2019. Kannalife, Inc. was founded in 2010 and is based in Doylestown, Pennsylvania.